David Kabakoff, PhD

Executive Partner

David Kabakoff joined Sofinnova Ventures as an Executive Partner in 2007. David has 30 years of experience leading technology and product development programs in the pharmaceutical, biopharmaceutical, and drug delivery fields. He currently serves as Chairman of NextCure and Lineagen, and as Director of Antiva Biosciences and Dauntless Pharmacueticals. Previously he served as Chairman for Trius Therapuetics and Amplimmune, Inc., as well as a Director for InterMune, Inc. and Allylix, Inc.

David co-founded Salmedix, Inc., a developer of cancer drug treatments, and served as the company’s Chairman and Chief Executive Officer. In June 2005, David negotiated the acquisition of Salmedix by Cephalon, Inc. David also held the positions of Executive Vice President of Dura and President and Chief Executive Officer of Spiros Development Corp. while at Dura Pharmaceuticals, a specialty respiratory pharmaceutical and pulmonary drug delivery company. Earlier, David was also employed as Chief Executive Officer of Corvas International and held senior executive positions with Hybritech, Inc.

David received his Ph.D. from Yale University and his B.A. from Case Western Reserve University.

Assistant: Lesley Weber Email: lesley@sofinnova.com.


(858) 551-4890


Representative Investments

  • Intellikine   Acquired - Millennium/Takeda
  • Trius Therapeutics   Acquired - Cubist